KDR and thrombotic microangiopathy: • Inhibits vascular endothelial and microvascular endothelial cell proliferation and survival• Inhibits VEGFR2 (KDR) leading to proteinuria and thrombotic microangiopathy• Inhibits angiopoietin receptor TIE-2 (KDR) and FGFR kinases leading to vascular toxicity• Induces human umbilical venous endothelial cells apoptosis and necrosis (in vitro)• Potently inhibits VEGFR leading to HTN*• Inhibits mast-cell KIT receptor, thus impairs endothelial cell regeneration, or sensitizes the endothelium to atherosclerosis generation#